Medical University of Vienna-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014351)
◆英語タイトル:Medical University of Vienna - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014351
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:48
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:オーストリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Medical University of Vienna (MUV) is a medical research institute that offers educational services. The institute provides research and education services in the field of medical science. Its research services include project submission, clinical and preclinical studies, research funding, biobank and medical engineering, patenting, research documentation and others. MUV’s courses include clinical research, gender medicine, health care management, interdisciplinary pain medicine, medical hypnosis, periodontology, toxicology, and dental hypnosis, among others. The institute’s outpatient services include immunization services, genetic counseling, donation of bodies to research, forensic medicine, and others. It provides medical research in allergology, immunology, infectiology, oncology, neuroscience and psychiatric-psychosocial science, vacular medicine, and bildgebung. MUV is headquartered in Vienna, Austria.

Medical University of Vienna – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Medical University of Vienna, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Medical University of Vienna, Medical Devices Deals, 2011 to YTD 2017 10
Medical University of Vienna, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Medical University of Vienna, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Cyxone Partners with Medical University of Vienna 12
Imugene Enters Into Partnership with Medical University of Vienna 13
AFFiRiS Enters Into Co-Development Agreement With Medical University Of Vienna 14
Licensing Agreements 15
MedUni Vienna Enters into Licensing Agreement with Accequa 15
Medical University of Vienna Enters Into Licensing Agreement With Akron Molecules 16
Asset Transactions 17
Cyxone to Acquire T20K Patent Portfolio from Medical University of Vienna 17
Cyxone Acquires Cyclotide Patent Rights from MedUni Vienna and University Medical Center Freiburg 18
Medical University of Vienna – Key Competitors 19
Medical University of Vienna – Key Employees 20
Medical University of Vienna – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Strategy And Business Planning 22
Oct 19, 2017: Fresenius Vamed opens Institute for Gender Medicine 22
Government and Public Interest 23
Oct 30, 2017: HPV: Vaccination and test reduce cancer risk by more than 90% 23
Oct 20, 2017: Vienna researchers explore a new way of specific drug delivery using liposomes 24
Oct 19, 2017: Serotonin helps to promote liver regeneration following liver resection for liver cancer – but also supports early tumour regrowth 25
Oct 17, 2017: Possible approach discovered for treating Multiple Sclerosis 27
Sep 19, 2017: Tumor-infiltrating B Lymphocytes Promote Melanoma Progression and Resistance to Therapy 28
Aug 21, 2017: Immune system can be modulated by targeted manipulation of cell metabolism 29
Jul 24, 2017: Potential biomarker discovered to allow more precise classification of malignant brain tumours in children 30
Jul 18, 2017: Cause of chemoresistance in small cell lung cancer discovered 31
Oct 24, 2016: International team discovers deficiency of RASGRP1 gene causes newly discovered human immunodeficiency 32
Jul 18, 2016: Potential new treatment to combat lethal fungal infections 34
Jun 27, 2016: Prognostic factor indicates risk of cancer recurrence following radical prostatectomy 35
Apr 14, 2016: Specific gene in the tumor determines the effectiveness of cancer treatment 36
Apr 04, 2016: Discovery of a new approach to the treatment of Lupus 37
Mar 30, 2016: HPV: cervical peeling as a treatment for precancerous conditions 38
Mar 29, 2016: Transmissibility of Alzheimer’s: No clinical symptoms 39
Mar 25, 2016: Generous Advanced ERC Grants for MedUni Vienna Researchers 40
Mar 08, 2016: Renal cell carcinoma: therapy change can significantly improve treatment result 42
Feb 08, 2016: Migraine: Light therapy may bring new hope 43
Product News 44
Sep 20, 2017: Characterization of a Slowly Proliferating Population of Melanoma Cells with High Metastatic Properties 44
Mar 15, 2016: New treatment for Chronic Lymphatic Leukaemia could replace chemotherapy 45
Other Significant Developments 46
Oct 18, 2017: MedUni Vienna starts fund-raising for precision medicine 46
Sep 30, 2016: FOLSMART project – an improved treatment method for Rheumatoid Arthritis 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
Medical University of Vienna, Pharmaceuticals & Healthcare, Key Facts 2
Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Medical University of Vienna, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Medical University of Vienna, Deals By Therapy Area, 2011 to YTD 2017 9
Medical University of Vienna, Medical Devices Deals, 2011 to YTD 2017 10
Medical University of Vienna, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Cyxone Partners with Medical University of Vienna 12
Imugene Enters Into Partnership with Medical University of Vienna 13
AFFiRiS Enters Into Co-Development Agreement With Medical University Of Vienna 14
MedUni Vienna Enters into Licensing Agreement with Accequa 15
Medical University of Vienna Enters Into Licensing Agreement With Akron Molecules 16
Cyxone to Acquire T20K Patent Portfolio from Medical University of Vienna 17
Cyxone Acquires Cyclotide Patent Rights from MedUni Vienna and University Medical Center Freiburg 18
Medical University of Vienna, Key Competitors 19
Medical University of Vienna, Key Employees 20
Medical University of Vienna, Subsidiaries 21

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Medical University of Vienna-製薬・医療分野:企業M&A・提携分析(Medical University of Vienna - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆